Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-Derived Peptides for Oral Use in Antigen-Specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis.

Trial Profile

Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-Derived Peptides for Oral Use in Antigen-Specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2011

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors BioTech Tools
  • Most Recent Events

    • 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2009 Planned number of patients changed from 48 to 54 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top